The European Food Safety Authority (EFSA) is once again placing its scientific microscope over the genetically modified soybean MON 87769, and this time to decide whether to renew its authorization for food and feed use within the EU. This move affects biotech companies, farmers, food producers, regulatory bodies, and consumers who watch closely for any changes in the safety or market status of GMOs.
On 19 January 2026, EFSA published a Scientific Opinion stemming from its Panel on Genetically Modified Organisms. The document evaluates additional data submitted by Bayer CropScience LP concerning soybean MON 87769, known for producing stearidonic acid. The scope excludes cultivation but covers food and feed use within the EU.
The publication is an assessment of existing authorization renewal data rather than new legislation. It provides a scientific risk evaluation using post-market environmental and monitoring reports, literature reviews, updated bioinformatics, and assessments of possible new hazards or exposure changes. Notably, the document does not propose concrete policy changes, numerical targets, or new institutional mechanisms but rather reconfirms the conclusions of the original authorization.
EFSA’s scientific panel concludes there is no evidence of new risks, altered exposure, or scientific uncertainties that would affect the original risk assessment. This signals a continuation of the current authorization framework without expansion or restriction, maintaining the regulatory balance between safety oversight and GMO market presence.
Stakeholders experience different impacts from this assessment. Bayer CropScience and other biotech firms benefit from sustained market access without additional compliance burdens. Food producers relying on this soybean can maintain product formulations confidently. EU regulatory bodies benefit from updated scientific assurance that supports stability in oversight responsibilities. Consumers receive continued assurance on food safety, although cautious voices around GMO persist.
This EFSA opinion marks a critical checkpoint in the ongoing regulatory dialogue around GMO products. EFSA’s stance will inform the European Commission's final renewal decision and potentially prompt responses from EU Member States and the European Parliament. The process underscores EFSA’s central role in balancing innovation with consumer and environmental safety in Europe.
← Atlas › News › Agri-Food